ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
Portfolio Pulse from Vandana Singh
The supply of ADHD medications, including Vyvanse and Adderall, is dwindling in the US due to manufacturing complications and labor shortages at Teva Pharmaceutical Industries and Takeda Pharmaceutical. The shortage has reached a five-year high, with Vyvanse prescriptions surging in 2023.
June 21, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Takeda Pharmaceutical's Vyvanse faces low inventory due to manufacturing complications, with the issue expected to persist until September.
Takeda Pharmaceutical, a manufacturer of Vyvanse, is experiencing low inventory due to manufacturing complications. The increased demand for Vyvanse, resulting from shortages of other ADHD medications, has hindered their ability to maintain sufficient inventory. This may negatively impact Takeda's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
Teva Pharmaceutical Industries faces labor shortages, constraining the supply of brand-name and generic Adderall.
Teva Pharmaceutical Industries is the largest manufacturer of brand-name and generic Adderall. The labor shortage at the company has constrained the drug's supply, which may negatively impact its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50